Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
4.270
-0.230 (-5.11%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lyra Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 0.6 | 1.53 | 1.56 | 1.36 | 0.29 | - | Upgrade
|
| Revenue Growth (YoY) | -59.21% | -1.54% | 14.31% | 378.25% | - | - | Upgrade
|
| Cost of Revenue | 20.4 | 43.77 | 48.03 | 38.8 | 29.69 | 12.52 | Upgrade
|
| Gross Profit | -19.8 | -42.23 | -46.47 | -37.43 | -29.41 | -12.52 | Upgrade
|
| Selling, General & Admin | 12.61 | 18.5 | 19.06 | 17.56 | 14.21 | 9.69 | Upgrade
|
| Operating Expenses | 12.61 | 18.5 | 19.06 | 17.56 | 14.21 | 9.69 | Upgrade
|
| Operating Income | -32.41 | -60.73 | -65.53 | -54.99 | -43.62 | -22.21 | Upgrade
|
| Interest & Investment Income | 1.4 | 2.95 | 4.5 | 1.04 | 0.1 | 0.08 | Upgrade
|
| EBT Excluding Unusual Items | -31.01 | -57.78 | -61.03 | -53.95 | -43.51 | -22.13 | Upgrade
|
| Merger & Restructuring Charges | -2.9 | -10.9 | - | - | - | - | Upgrade
|
| Asset Writedown | - | -24.72 | -1.59 | -1.32 | - | - | Upgrade
|
| Pretax Income | -32.93 | -93.4 | -62.62 | -55.27 | -43.51 | -22.13 | Upgrade
|
| Income Tax Expense | 0.02 | 0.04 | 0.06 | 0.01 | - | - | Upgrade
|
| Net Income | -32.95 | -93.44 | -62.68 | -55.28 | -43.51 | -22.13 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.12 | Upgrade
|
| Net Income to Common | -32.95 | -93.44 | -62.68 | -55.28 | -43.51 | -22.24 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 12.03% | 30.74% | 64.72% | 132.83% | 51.17% | - | Upgrade
|
| EPS (Basic) | -22.93 | -71.75 | -62.93 | -91.41 | -167.54 | -129.46 | Upgrade
|
| EPS (Diluted) | -22.93 | -71.75 | -62.93 | -91.41 | -167.54 | -129.46 | Upgrade
|
| Free Cash Flow | -34.11 | -72.35 | -64.35 | -43.55 | -29.21 | -22.92 | Upgrade
|
| Free Cash Flow Per Share | -23.74 | -55.56 | -64.60 | -72.02 | -112.45 | -133.40 | Upgrade
|
| Operating Margin | -5401.33% | -3959.13% | -4205.90% | -4034.48% | -15303.51% | - | Upgrade
|
| Profit Margin | -5491.17% | -6090.94% | -4023.11% | -4055.61% | -15267.72% | - | Upgrade
|
| Free Cash Flow Margin | -5684.50% | -4716.36% | -4130.36% | -3195.08% | -10247.37% | - | Upgrade
|
| EBITDA | -31.9 | -60.26 | -65.25 | -53.92 | -42.61 | -22.11 | Upgrade
|
| D&A For EBITDA | 0.51 | 0.47 | 0.28 | 1.07 | 1 | 0.1 | Upgrade
|
| EBIT | -32.41 | -60.73 | -65.53 | -54.99 | -43.62 | -22.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.